Outlook Therapeutics, Inc. (then Oncobiologics, Inc.) — Form 10-Q
Reporting period: Fiscal third quarter and nine months ended June 30, 2018. The filing identifies the registrant as Oncobiologics, Inc.; it does not use the name Outlook Therapeutics.
Business context
The company was a clinical-stage biopharmaceutical business developing and manufacturing monoclonal antibody therapeutics. It had no products approved for sale; reported revenue came from collaboration and licensing agreements. Its lead candidate, ONS-5010, was being prepared for clinical trials, while planned Phase 3 trials for ONS-3010 and ONS-1045 were deferred pending development partners.
Financial performance and position
| Metric | Three months ended June 30, 2018 | Nine months ended June 30, 2018 | Comparable 2017 period |
|---|---|---|---|
| Collaboration revenue | $0.77 million | $2.32 million | $0.30 million and $0.91 million |
| Operating expenses | $7.99 million | $19.55 million | $7.64 million and $33.88 million |
| Operating loss | $7.22 million | $17.23 million | $7.34 million and $32.97 million |
| Net loss | $8.43 million | $17.89 million | $5.33 million and $32.48 million |
| Net loss per share, basic | $0.26 | $1.24 | $0.22 and $1.37 |
Nine-month net loss attributable to common stockholders was $35.37 million, including a $15.74 million beneficial-conversion charge and $1.74 million of Series A dividends and related settlement. Nine-month collaboration revenue was recognized from deferred upfront payments, including the GMS Tenshi arrangement; it was not product-sales revenue. Gross margin is not reported.
- Cash and liquidity: Cash was $11.80 million at June 30, 2018, versus $3.19 million at September 30, 2017. Current assets were $13.13 million and current liabilities $32.26 million.
- Cash flow: Nine-month operating cash use was $24.65 million; investing cash use was $1.52 million; financing provided $34.77 million. Cash increased $8.61 million.
- Debt and obligations: Senior secured notes had $13.5 million principal due in December 2018 ($12.84 million net carrying value). Stockholder notes of $4.61 million were payable on demand. Capital lease obligations totaled about $4.20 million, including current and long-term portions.
- Balance sheet: Total liabilities were $43.35 million; accumulated deficit was $204.11 million; stockholders’ deficit was $13.20 million. Common shares outstanding were 72.20 million at June 30, 2018 and 72.20 million at August 10, 2018.
Changes versus prior comparable periods
- Quarterly revenue rose by $0.47 million, primarily from recognition of GMS Tenshi collaboration upfront payments. Nine-month revenue increased by $1.41 million for the same reason.
- Quarterly R&D expense increased $1.64 million, largely reflecting $1.69 million of ONS-5010 spending. Nine-month R&D expense fell $10.15 million, driven by reduced ONS-3010/ONS-1045 development, a $3.23 million favorable contract settlement, and lower personnel costs; ONS-5010 spending partly offset the decline.
- G&A expense declined $1.29 million for the quarter and $4.18 million for nine months, mainly because of lower stock-based compensation as pre-IPO awards completed vesting.
- Operating cash use increased from $15.58 million to $24.65 million for nine months, while financing inflows increased, principally from preferred-stock and common-stock/warrant transactions with controlling stockholder GMS Tenshi.
- Quarterly net loss worsened despite a slightly lower operating loss, in part because the prior-year period included $3.75 million of noncash warrant-liability income. Nine-month net loss improved versus 2017, including a $3.15 million New Jersey tax-credit/NOL sale benefit; the filing also records a $1.25 million debt-extinguishment loss.
Outlook, risks and unusual items
- Management said June 30 cash was expected to fund operations into November 2018, excluding debt repayment. The filing states substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, limited cash, $13.5 million of notes due in December 2018, and $4.6 million of demand debt. Additional financing was needed, with no assurance it could be obtained; failure could require workforce reductions, program discontinuation, asset liquidation, or bankruptcy protection.
- Potential funding sources included equity or debt offerings, strategic partnerships and licensing, and contract development and manufacturing services. The company reported a Sonnet Biotherapeutics CDMO contract with a maximum estimated value of approximately $5.1 million if all milestones were met; the filing does not establish that this full amount would be earned.
- In May and June 2018, GMS Tenshi invested $15 million for common stock and warrants; the warrants cover up to 20.51 million shares at $0.975 per share. In June, GMS Tenshi converted Series A preferred shares into 31.57 million common shares. In July, remaining Series A shares were exchanged for Series A-1 preferred shares with 10% compounded quarterly dividends and increased redemption and liquidation preferences.
- Other key risks include clinical-trial and regulatory uncertainty, dependence on partners and future financing, competition, and eventual market acceptance. Management said disclosure controls were effective; it reported no material change in internal control over financial reporting and no material pending legal claims.
Investor verification priorities
- Confirm the issuer/name and share count, and review the July 2018 Series A-1 exchange terms, including redemption and liquidation preferences.
- Assess the timing and source of funding needed beyond the stated November 2018 cash runway, and the ability to repay or refinance notes due in December 2018 and demand stockholder notes.
- Check subsequent financing, partnership, and CDMO developments, including whether Sonnet milestones were achieved and related-party arrangements were conducted on appropriate terms.
- Verify ONS-5010 trial progress and whether ONS-3010 and ONS-1045 secured partners to restart planned Phase 3 development.
- Reconcile common-stock dilution from preferred conversions, outstanding warrants, and potential future financing with the filing’s reported losses and cash burn.